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Disseminated intravascular coagulation (DIC) is categorized into bleeding, organ failure, massive bleeding, and
non-symptomatic types according to the sum of vectors for hypercoagulation and hyperfibrinolysis. The British
Committee for Standards in Haematology, Japanese Society of Thrombosis and Hemostasis, and the Italian Society
for Thrombosis and Haemostasis published separate guidelines for DIC; however, there are several differences
between these three sets of guidelines. Therefore, the International Society of Thrombosis and Haemostasis (ISTH)
recently harmonized these differences and published the guidance of diagnosis and treatment for DIC. There are
three different diagnostic criteria according to the Japanese Ministry Health, Labour and Welfare, ISTH, and Japanese
Association of Acute Medicine. The first and second criteria can be used to diagnose the bleeding or massive
bleeding types of DIC, while the third criteria cover organ failure and the massive bleeding type of DIC. Treatment
of underlying conditions is recommended in three types of DIC, with the exception of massive bleeding. Blood
transfusions are recommended in patients with the bleeding and massive bleeding types of DIC. Meanwhile,
treatment with heparin is recommended in those with the non-symptomatic type of DIC. The administration of
synthetic protease inhibitors and antifibrinolytic therapy is recommended in patients with the bleeding and massive
bleeding types of DIC. Furthermore, the administration of natural protease inhibitors is recommended in patients
with the organ failure type of DIC, while antifibrinolytic treatment is not. The diagnosis and treatment of DIC should
be carried out in accordance with the type of DIC.
Keywords: Disseminated intravascular coagulation (DIC), Bleeding type, Organ failure type, Massive bleeding type,
Non-symptomatic type, GuidelinesIntroduction
Disseminated intravascular coagulation (DIC) is a syn-
drome characterized by the systemic activation of blood
coagulation, which generates intravascular thrombin and
fibrin, resulting in the thrombosis of small- to medium-
sized vessels and ultimately organ dysfunction and severe
bleeding [1,2]. DIC may result as a complication of infec-
tion, solid cancers, hematological malignancies, obstetric
diseases, trauma, aneurysms, and liver diseases, etc., each
of which presents characteristic features related to the
underlying disorder. The diagnosis and treatment of DIC
must therefore consider these underlying etiological* Correspondence: wadahide@clin.medic.mie-u.ac.jp
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stated.features. The type of DIC is related to the underlying dis-
order. Three guidelines for diagnosis and treatment of
DIC [3-5] have been published in the literature by the
British Committee for Standards in Haematology (BCSH),
Japanese Society of Thrombosis and Hemostasis (JSTH),
and Italian Society for Thrombosis and Haemostasis
(SISET). Although these three guidelines are broadly simi-
lar, there are variations in several recommendations re-
garding DIC treatment. Therefore, the subcommittee for
DIC of the Scientific and Standardization Committee
(SSC)/International Society of Thrombosis and Haemosta-
sis (ISTH) harmonized these three guidelines in a report
entitled, Guidance for the diagnosis and treatment of DIC
from harmonization of the recommendations from three
guidelines [6] (Table 1). The present review describestd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
Table 1 Differences in recommendations among three guidelines from BCSH, JSTH, and SISET and harmonized
ISTH/SSC guidance
BCSH JSTH SISET ISTH/SSC
Scoring system for DIC R; grade C Ra R; grade C R; high quality
Single test analysis for DIC NR NRa NR; grade D R high quality
Treatment of underlying disease R; grade C R; consensus R; cornerstone R; moderate quality
Platelet concentration R; grade C R; consensus R; grade D R; low quality
FFP R; grade C R; consensus R; grade D R; low quality
Fibrinogen, cryoprecipitate R; grade C Disregard R; grade D R; low quality
FVIIa Disregard Disregard NR; grade D NM
UFH (treatment) R; grade C R; level C NR; grade D R; low quality
UFH (prophylaxis for VTE) R; grade A Disregard R R; high quality
LMWH Disregard R; level B2 R; grade D Preferred to UFH
Heparin sulfate Disregard R; level C NM
Synthetic protease Disregard R; level B2 NR; grade D NM
rhAPC R; grade A Disregard R; grade D Need for further Ed from RCT
AT NR; grade A R; B1 NR; grade D Need for further Ed from RCT
rhTM Disregard Disregard NR; grade B Need for further Ed from RCT
Antifibrinolytic agents R; grade C NR; level D R; low quality
Plasma exchange Disregard Disregard NR; grade D NM
R, recommendation; NR, not recommendation; Ra, suggestive recommendation; NM, not mention; Ed, evidence; FFP, fresh frozen plasma; PCC, FVIIa, activated
coagulation factor VII; UFH, unfractionated heparin; LMWH, low molecular weight heparin; rh, recombinant human; APC, activated protein C; AT, antithrombin; TM,
thrombomodulin; RCT, randomized control trial.
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of DIC related to the type of DIC.
Review
Pathophysiology of DIC
Abnormalities of the hemostatic system in patients with
DIC result from the sum of vectors for hypercoagulation
and hyperfibrinolysis (Figure 1). When the vector for
hyperfibrinolysis is remarkable and dominant, bleedingFigure 1 Bleeding, organ failubre, massive bleeding, and
non-symptomatic types of DIC.is the primary symptom; this type is called the bleeding
type or hyperfibrinolysis predominance type of DIC.
This form of DIC is often seen in patients with
leukemia, such as acute promyelocytic leukemia (APL),
obstetric diseases, or aortic aneurysms [2,7]. On the
other hand, when the vector for hypercoagulation is re-
markable and dominant, organ failure is the main symp-
tom; this type of DIC is called the organ failure type,
hypercoagulation predominance type or hypofibrinolysis
type of DIC. This form of DIC is often observed in pa-
tients with infection, particularly sepsis. An increase in
the level of plasminogen activator inhibitor I (PAI-I) in-
duced by markedly increased levels of cytokines [8,9]
and lipopolysaccharide (LPS) [2,7] in the blood has been
reported to a cause of hypofibrinolysis. Moreover, neu-
trophil extracellular traps (NETs) [10], which release
DNA with histone, neutrophil elastase, and cathepsin G
in order to trap and kill pathogens, are present in pa-
tients with sepsis. Histones promote the apoptosis of
vascular endothelial cells and platelet aggregation [11],
while neutrophil elastase and cathepsin G decompose tis-
sue factor pathway inhibitor (TFPI) in order to promote
thrombus formation [12]. Moreover, high mobility group
box 1 (HMGB-1) [13] is emitted from injured and dead
cells in order to enhance the inflammatory reaction.
When both vectors for hypercoagulation and hyper-
fibrinolysis are remarkable and strong, major bleeding
occurs, followed by death, if a sufficient amount of blood
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bleeding or consumptive type of DIC. This form of DIC
is observed in patients who exhibit major bleeding after
major surgery or in those with obstetric diseases.
When both vectors are weak, there are almost no clinical
symptoms, although abnormalities in clinical laboratory
tests are observed; this type of DIC is called the non-
symptomatic type of DIC or pre-DIC [14,15]. In a retro-
spective study [15], the treatment of pre-DIC was reported
to be effective. The diagnosis and treatment of the four
types of DIC differ [3]. Furthermore, the diagnosis and
treatment of DIC is complicated by the fact that the types
of DIC may shift or change. Patients with DIC caused by
sepsis (organ failure type), hematological malignancy, or
obstetrics (bleeding type) can be successfully treated for
DIC, whereas DIC associated with solid cancers may not
respond to standard treatments [16]. As DIC associated
with solid cancers differs from the above four types of DIC,
it should be analyzed separately.
Diagnosis of DIC
Scoring system
Various underlying clinical conditions can have an effect
on the laboratory parameters that are usually obtained
to diagnose DIC, such as global coagulation tests, the
platelet count, prothrombin time (PT), and the fibrino-
gen, fibrinogen, and fibrin degradation products (FDPs).
In order to facilitate the diagnostic process for detecting
DIC, the use of a scoring system is recommended by
each of the four different guidelines [3-6]. Three diffe-
rent diagnostic criteria incorporating similar global co-
agulation tests have been established by the ISTH/
SSC [1], Japanese Ministry Health, Labour and Welfare
(JMHLW) [17], and Japanese Association of Acute
Medicine (JAAM) [18]. The JMHLW score is well corre-
lated with the severity of DIC and can be used to predict
the outcome of the disease [14]. The ISTH overt DIC
score is useful and specific for diagnosing DIC due to in-
fective and non-infective etiologies [13,19]. The JAAM
score is sensitive for detecting septic DIC and is corre-
lated with the ISTH and JMHLW scores and disease
outcome [13,18]. A prospective study in Japan reported
no significant differences in the odds ratio for predicting
DIC outcomes among these three diagnostic criteria
[20], suggesting that the identification of molecular
hemostatic markers and changes of global coagulation
tests is required in addition to the application of scoring
systems. The use of a combination of tests repeated over
time in patients with suspected DIC can be used to diag-
nose the disorder with reasonable certainty in most
cases [21-23]. A template for a non-overt-DIC scoring
system, including global coagulation tests, changes in
global coagulation tests as well as hemostatic molecular
markers, has been proposed [1,24,25].The bleeding type of DIC can be easily diagnosed using
the ISTH overt-DIC [1] and JMHLW [17] criteria, while
the organ failure type of DIC is diagnosed according to
the JAAM diagnostic criteria [18]. The massive bleeding
(consumptive) type of DIC can be diagnosed using any of
the three diagnostic criteria [1,17,18]; however, it is diffi-
cult to diagnose the non-symptomatic type of DIC using
these criteria. The use of hemostatic molecular markers is
required to diagnose the non-symptomatic type of DIC.
Laboratory tests
Global coagulation tests provide important evidence re-
garding the degree of coagulation factor activation and
consumption. Although the PT is prolonged in approxi-
mately 50% of patients with DIC at some point during
their clinical course [21], abnormalities are often ob-
served in patients with liver disease or vitamin K defi-
ciency. A reduction in the platelet count or clear
downward trend in subsequent measurements is a sensi-
tive sign of DIC [3], although this pattern is also ob-
served in patients with bone marrow disorders. A
reduced fibrinogen level is a valuable indicator regarding
a diagnosis of DIC due to leukemia or obstetric diseases;
however, it is not observed in most septic DIC patients
[3]. Elevated fibrin-related markers (FRMs), such as FDP
[26], D-dimer [27], or soluble fibrin (SF), reflect fibrin
formation. SF [28] assays offer theoretical advantages in
detecting DIC, more closely reflecting the effects of
thrombin on fibrinogen, although the half-life is short. It
is important to consider that many conditions, such as
trauma, recent surgery, bleeding, or venous thrombo-
embolism (VTE), are associated with elevated FRMs. Re-
ductions in the levels of natural anticoagulants, such as
antithrombin (AT) and protein C, are common in pa-
tients with DIC. Although measuring the AT activity is
useful for achieving the full efficacy of heparin [29], this
parameter cannot be quickly and easily measured in all
hospitals. These activities are correlated with the liver
function and/or concentration of albumin. A reduced
ADAMTS13 (a disintegrin-like and metalloproteinase
with thrombospondin type 1 motifs 13) activity and ele-
vated soluble thrombomodulin (TM), PAI-I, and von
Willebrand factor propeptide levels are often observed
in patients with DIC and have been shown to have prog-
nostic significance [30-32]. The biphasic waveform of
the activated partial thromboplastin time (APTT) has
been shown to be associated with DIC and appears to
have a positive predictive value for the disease [33,34].
Although many attractive markers for DIC have been re-
ported, no single marker can be used to diagnose DIC
alone (Table 2). Therefore, the above four guidelines
[3-6] recommend that DIC could not be diagnosed ac-
cording to the level of a single marker but rather based
on the combination of laboratory markers. Among the
Table 2 Laboratory tests for DIC
Abnormality in DIC Other cause for the abnormality Adequate type of DIC
PT Prolongation Liver dysfunction, vitamin K deficiency OF, BL, MB
FDP, D-dimer Elevation Venous thromboembolism, operation BL, NS, OF
Fibrinogen Reduction Liver dysfunction BL, MB
Platelet count Reduction Bone marrow disorders OF, MB, BL, NS
AT/PC Reduction Liver dysfunction, capillary leak syndrome OF
SF/TAT Elevation Venous thromboembolism, operation OF, NS, BL, MS
TM Elevation Renal dysfunction, organ failure OF
VWFpp, PAI-I Elevation Organ failure OF
ADATMTS13 Reduction Liver dysfunction, thrombotic microangiopathy OF
APTT Biphasic waveform Infection OF
PPIC Elevation Venous thromboembolism, operation BL, MB
PT, prothrombin time; FDP, fibrinogen and fibrin degradation products; SF, soluble fibrin; AT, antithrombin; PC, protein C; TAT, thrombin AT complex; VWFpp, von
Willebrand factor propeptide; PAI-I, plasminogen activator inhibitor-I; APTT, activated partial thromboplastin time; PPIC, plasmin-plasmin inhibitor complex; OF,
organ failure type of DIC; BL, bleeding type of DIC; MB, massive bleeding type of DIC; NS, non-symptomatic type of DIC.












Underlying conditions R R R
Blood transfusion R R





Natural protease inhibitor R NR
Antifibrinolytic treatment NR NR R R
R, recommended; NR, not recommended.
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portant parameters for diagnosing the massive bleeding
type of DIC, while fibrinogen, FDP, and plasmin-plasmin
inhibitor complex (PPIC) are important for detecting the
bleeding type of DIC. Meanwhile, platelets, PT, and AT
are important for diagnosing the organ failure type of
DICand hemostatic molecular markers, such as SF and
the thrombin-AT complex, are important for diagnosing
the non-symptomatic type of DIC.
Treatment of DIC
Treatment of the underlying disease
The cornerstone of DIC treatment is providing treat-
ment for the underlying disorders, such as the adminis-
tration of antibiotics or surgical drainage in patients
with infectious diseases and anticancer drugs or surgery
in patients with malignant diseases. All four guidelines
[3-6] agree on this point, although there is no high-
quality evidence for the efficacy of treating the under-
lying disorder in DIC patients. DIC spontaneously resolves
in many cases when the underlying disorder is properly
managed and improved. However, some cases require
additional supportive treatment specifically aimed at ab-
normalities in the coagulation system. A randomized con-
trolled trial (RCT) of the use of all-trans retinoic acid
(ATRA) compared with conventional chemotherapy in pa-
tients with APL showed that the mortality rate was sig-
nificantly lower in the ATRA group [35]. ATRA exerts
differential effects on APL progression, as well as anti-
coagulant and antifibrinolytic effects [36]. Similarly, seve-
ral RCTs of the treatment of sepsis [37-42] and DIC [43]
have shown parallel improvements in coagulation de-
rangement and DIC, although the data have not always
been concordant. Treating the underlying disorder is first
required in patients with bleeding, organ failure, and non-
symptomatic types of DIC, while blood transfusions areneeded in patients with the massive bleeding type of DIC
(Table 3).
Blood transfusion
Markedly low levels of platelets and coagulation factors,
particularly fibrinogen, may increase the risk of bleeding.
The above four guidelines [3-6] recommended the ad-
ministration of platelet concentrate (PC) and fresh fro-
zen plasma (FFP) in DIC patients with active bleeding or
those at high risk of bleeding requiring invasive proce-
dures, without high-quality evidence. The threshold for
transfusing platelets depends on the clinical state of the
DIC patient. In general, PC is administered in DIC pa-
tients with active bleeding and a platelet count of ≦50 ×
109/l. A much lower threshold of 10 to 20 × 109/l is
adopted in non-bleeding patients who develop DIC after
undergoing chemotherapy. PC may be administered at
higher levels in patients perceived to be at high risk of
bleeding based on other clinical or laboratory features
[44]. The transfusion of PC or FFP is usually performed
in patients with the massive bleeding or bleeding types
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order to correct coagulation defects associated with a pro-
longed APTT or PT (greater than 1.5 times the normal
value) or decreased fibrinogen level (less than 1.5 g/dl).
An initial dose of 15 ml/kg of FFP is clinically recom-
mended and usually administered. As the consequences of
volume overload must be considered in this context,
smaller volumes of prothrombin complex concentrate
may be useful in this setting. As specific deficiencies in fi-
brinogen associated with the massive bleeding type of DIC
can be corrected with the administration of purified fi-
brinogen concentrates or cryoprecipitate, three of the
guidelines recommended these treatments (Table 3). The
response to blood component therapy should be moni-
tored both clinically and with repeated assessments of the
platelet count and coagulation parameters following the
administration of these components. The efficacy and
safety of recombinant factor VIIa in DIC patients with
life-threatening bleeding are unknown, and this treatment
should be used with caution or as part of a clinical trial.
Heparin
Although the administration of anticoagulant treatment is
a rational approach based on the notion that DIC is char-
acterized by extensive activation of coagulation, there are
several differences in the recommendations for the use of
heparin in DIC patients between the four guidelines
(Table 1) [3-6]. Therapeutic doses of heparin should be
considered in cases of DIC in which thrombosis predomi-
nates. A small RCT showed that low molecular weight
heparin (LMWH) is superior to unfractionated heparin
(UFH) for treating DIC [45], suggesting that the use of
LMWH is preferred to that of UFH in these cases. The
level of inhibition achieved with LMWH is higher for acti-
vated coagulation factor Xa (Xa) than for thrombin. Pa-
tients with DIC are at high risk of VTE events, and the
administration of VTE prophylaxis using UFH, LMWH,
and/or mechanical methods has become the standard of
care in patients with DIC [46,47]. Although experimental
studies have shown that heparin can at least partly inhibit
the activation of coagulation in the setting of DIC [48],
there are no RCTs demonstrating that the use of heparin
in patients with DIC results in improvements in clinically
relevant outcomes. A recent large trial of patients with se-
vere sepsis showed a non-significant benefit of low-dose
heparin on the 28-day mortality and underscored the im-
portance of not discontinuing heparin treatment in pa-
tients with DIC and abnormal coagulation parameters
[29]. Meanwhile, the 28-day mortality is lower in placebo
groups treated with heparin than in placebo groups with-
out heparin according to subclass analyses [49] of RCT of
severe sepsis [37,38,42]. Although it is not easy to quickly
measure the AT level in all hospitals in order to de-
cide whether to administer urgent heparin treatment,measuring this parameter is useful for achieving the full
efficacy of heparin. The administration of heparin is not
recommended in patients with bleeding or massive bleed-
ing type of DIC due to the increased risk of bleeding,
although it is recommended in those with the non-
symptomatic type of DIC in order to prevent the onset of
deep vein thrombosis (DVT) (Table 3).
Anti-Xa agents
Both Fondaparinux® and Danaparoid sodium® activate
AT specifically to inhibit Xa. Treatment with Fondapari-
nux® is recommended for the prophylaxis of DVT after
orthopedic surgery; however, there is little evidence to
support its use in critically ill patients and those with
other type of DIC. Danaparoid sodium® is used to treat
DIC in Japan, although no RCTs have shown any reduc-
tions in mortality or the rate of resolution of DIC. There
is significant evidence for the use of these drugs as
prophylaxis for DVT [50,51]; however, there is little evi-
dence for the use of these agents in patients with DIC, and
they are not recommended in those with the bleeding or
massive bleeding type of DIC (Table 3). These drugs are
also not recommended in patients with renal failure.
Synthetic protease inhibitors
Synthetic protease inhibitors, such as Gabexate mesilate®
and nafamostat®, exhibit multiple-functions, including
antagonistic effects on the kinin/kallikrein system, fibrin-
olysis, complement system, and coagulation system.
Gabexate mesilate® and nafamostat® have been frequently
used and evaluated in Japan [13,52,53]; however, there
are no RCTs showing any reductions in mortality or
improvements in the rate of resolution of DIC. As
these drugs have mild anticoagulant and antifibrinolytic
effects, they are often used in patients with the bleed-
ing, massive bleeding, and non-symptomatic types of
DIC (Table 3).
Natural protease inhibitor
The use of agents capable of restoring dysfunctional
anticoagulant pathways in patients with DIC has been
studied extensively. Although there are many RCTs of
clinically ill patients, almost all RCTs have been carried
out in patients with sepsis, with few RCTs of patients
with DIC, suggesting that BCSH and SISET determined
their recommendations for DIC treatment based on
studies of sepsis, not DIC.
AT and the heparin/heparinoid complex primarily in-
hibits Xa and thrombin, while the APC/TM system in-
hibits thrombin, FVa, and FVIIIa (Figure 2). Each of the
four guidelines [3-6] provides different recommenda-
tions regarding the use of anticoagulant factor concen-
trates (Table 1). A large-scale multicenter RCT directly
assessing the effects of AT concentrate on mortality in
Figure 2 Regulation of the coagulation system.
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tions in those treated with AT concentrate [37]. Interes-
tingly, the subgroup of patients with DIC and who did
not receive heparin showed a remarkable survival benefit
[54]; however, this finding requires prospective vali-
dation. In one prospective multicenter survey, the efficacy
of AT was higher in the 3,000 units/day group than in the
1,500 units/day group [55].
The clinical efficacy of recombinant human activated
protein C (rhAPC) in patients with severe sepsis was dem-
onstrated in a large RCT [38], although a prospective trial
of septic patients with relatively low disease severity did
not show any benefits of rhAPC therapy [39]. The with-
drawal of rhAPC from sepsis treatment regimens was pro-
posed after an RCT of septic shock failed to show any
benefits [40]. Meanwhile, treatment with plasma-derived
APC improved outcomes in a small RCT [56] in Japan;
however, the drug is not approved for the treatment of
DIC. There are no useful RCTs of the administration of
protein C concentrate to treat sepsis or DIC.
One RCT comparing treatment with rhTM with that of
UFH [43] showed that rhTM therapy significantly increased
the rate of resolution of DIC, although mortality was not
significantly decreased. In another study of DIC, treatment
with rhTM relatively reduced mortality and significantly re-
duced the severity of organ failure compared to a placebo
[57]. Another RCT of severe sepsis showed that the admi-
nistration of rhTM tended to improve mortality [41].
The administration of AT, rhTM, or APC may be con-
sidered in DIC patients. Further prospective evidence
from RCTs confirming a benefit is required [6]. Treat-
ment with AT and rhTM is recommended in patients
with the organ failure type of DIC (Table 3).
Antifibrinolytic treatment
Antifibrinolytic agents are effective in treating bleeding,
although the use of these drugs in patients with theorgan failure or non-symptomatic type of DIC is gene-
rally not recommended [58]. An exception may be made
in those with the bleeding or major bleeding type of
DIC. The four guidelines [3-6] exhibit some differences
in these recommendations (Table 1). One study of APL
demonstrated a beneficial effect of antifibrinolytic agents
in this situation [59]; however, cases complicated with
severe thrombosis due to the combined use of ATRA
and tranexamic acid have been documented [60]. A re-
cent RCT [61] showed that treatment with tranexamic
acid significantly reduces the mortality of patients with
trauma. The administration of antifibrinolytic agents in
these cases must occur in the early period of manage-
ment before the levels of PAI-1 and other endogenous
antifibrinolytics become elevated.
Conclusions
In conclusion, DIC is categorized into bleeding, organ
failure, massive bleeding, and non-symptomatic types.
The diagnosis and treatment of DIC should be carried
out in accordance with the type of DIC based on the
four guidelines on DIC.
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